Parabilis Medicines raised $305 million in an oversubscribed Series F to advance its Helicon‑derived corkscrew peptide platform and lead candidate zolucatetide toward later‑stage studies. The round, led by RA Capital, Fidelity and Janus Henderson, increases the company’s war chest as it prepares to scale clinical development and consider an eventual public offering. Parabilis positions its peptide modality to tackle intracellular and ‘undruggable’ targets by delivering structured helical peptides into cells. Management said preliminary Phase 1/2 data were encouraging and that the financing supports expanded trials and regulatory planning. Investors and market commentators flagged Parabilis as a high‑profile example of renewed VC appetite for companies pursuing novel modalities, especially those that can address oncology targets inaccessible to conventional small molecules or antibodies.